Hamura, Japan

Norihiro Iibuchi


Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 52(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Norihiro Iibuchi: Innovator in Thiazolidinedione Derivatives

Introduction

Norihiro Iibuchi is a notable inventor based in Hamura, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of thiazolidinedione derivatives. With a total of 2 patents, his work focuses on innovative methods for preparing these compounds, which have important therapeutic applications.

Latest Patents

Iibuchi's latest patents include advancements in thiazolidinedione derivatives. One of his notable inventions is a thiazolidinedione derivative that exhibits excellent effects in reducing blood sugar levels and lipid concentrations in blood. This compound is particularly useful as a therapeutic agent for treating diabetes mellitus. Additionally, he has developed amino acid derivatives that possess anti-CCK activity, showcasing his diverse expertise in medicinal chemistry.

Career Highlights

Throughout his career, Iibuchi has worked with reputable companies such as Senga Pharmaceutical Laboratory Inc. and Tobishi Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to refine his skills and contribute to significant advancements in pharmaceutical research.

Collaborations

Iibuchi has collaborated with esteemed colleagues, including Masashi Ogawa and Tadashi Morita. These partnerships have fostered a collaborative environment that enhances innovation and the development of new therapeutic agents.

Conclusion

Norihiro Iibuchi's contributions to the field of pharmaceuticals, particularly through his patents on thiazolidinedione derivatives, highlight his role as an influential inventor. His work continues to impact the treatment of diabetes mellitus and showcases the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…